Novo Nordisk has requested the FDA to dam manufacture of compounded copies of copyright, arguing that it’s far too tough to do safely. It’s the latest escalation in a brewing war amongst pharmaceutical businesses and compounders. The breakthroughs and improvements that we uncover brin